Combining an Immune Checkpoint Antibody with an Anti-Angiogenesis Inhibitor

A small phase I study combining the immune checkpoint antibody ipilimumab with the angiogenesis inhibitor antibody bevacizumab showed promising results in advanced melanoma patients in 2011. Now, researchers are continuing to study the combination of immunotherapy and anti-angiogenic agents to understand which patients could best benefit from such a combination. Continue reading…

Imaging Tumor Blood Vessels Could Help Optimize Melanoma Treatment

Melanomas that have spread can be treated by cutting off their blood supplies, but this only works in some people. Now there may be a way to predict who this anti-angiogenic therapy will benefit, according to findings reported at the American Association for Cancer Research’s 2013 meeting. The researchers analyzed computed tomography (CT) images of melanomas from 46 people who had undergone anti-angiogenic treatment. The images revealed that loss of tumor blood vessels was linked to survival, particularly in people who also had low levels of lactate dehydrogenase (LDH). Next, the researchers plan to test their findings in clinical studies.